When Genomic Reanalysis Leaves the Laboratory — Clinical Genetics in the Age of Consumer AI
NEJM AI · 25.06.2026 · 3 (7)
DOI: 10.1056/aie2600766 ↗Kurz gefasst
Editorial in der Zeitschrift NEJM AI, erschienen am 25.06.2026. Verfasst von Samuel G Finlayson und 1 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Pediatrics and Genetics, Seattle Children's Hospital, Seattle, WA, USA. Hauptthemen laut MEDLINE: Artificial Intelligence, Genomics, Genetic Testing. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben.
Abstract (Originalsprache)
AbstractReanalysis of previously unsolved genomic data is a recommended component of rare disease care and resolves a meaningful share of initially unsolved cases, but its high cost and uneven implementation mean that many eligible patients do not receive it. In this issue of NEJM AI, Jaech et al. performed reanalysis of unsolved cases using a general-purpose consumer AI platform and reached a new diagnosis in approximately 4.8% of cases despite minimal expert input. This poses central questions about the future of clinical genetics in an era of widely available consumer AI. We argue that, given converging legal access rights, increasingly capable consumer AI, and the urgency of undiagnosed disease, the expansion of patient-led genetic reanalysis seems inevitable irrespective of professional endorsement. We outline norms for safeguarding privacy, enabling voluntary data contribution, and accrediting the interpretive step, so that patient- and AI-derived findings can enter the clinical record through a recognized pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Departments of Pediatrics and Genetics, Seattle Children's Hospital, Seattle, WA, USA.
- Departments of Pediatrics and Genetics, University of Washington, Seattle, USA.
- Center for Genomic Medicine, Massachusetts General Hospital, Boston, USA.
- Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
ORCID-Profile: Samuel G Finlayson, Heidi L Rehm
Zitieren
APA
Finlayson, S. G., & Rehm, H. L. (2026). When Genomic Reanalysis Leaves the Laboratory — Clinical Genetics in the Age of Consumer AI. NEJM AI, 3(7). https://doi.org/10.1056/aie2600766
Vancouver
Finlayson SG, Rehm HL. When Genomic Reanalysis Leaves the Laboratory — Clinical Genetics in the Age of Consumer AI. NEJM AI. 2026;3(7). doi:10.1056/aie2600766
BibTeX
@article{Finlayson2026,
author = {Finlayson, Samuel G and Rehm, Heidi L},
title = {When Genomic Reanalysis Leaves the Laboratory — Clinical Genetics in the Age of Consumer AI},
journal = {NEJM AI},
year = {2026},
volume = {3},
number = {7},
doi = {10.1056/aie2600766}
}
EUVIMED